News
ANEB
0.4790
+0.86%
0.0041
Anebulo Pharmaceuticals Q2 EPS $(0.05) Beats $(0.13) Estimate
Benzinga · 1d ago
Anebulo Pharmaceuticals GAAP EPS of -$0.05
Seeking Alpha · 1d ago
Anebulo Pharma posts Q2 net loss of USD 2.0 million, down 20 percent
Reuters · 1d ago
*Anebulo Pharmaceuticals 2Q Loss/Shr 5c >ANEB
Dow Jones · 1d ago
Anebulo Pharmaceuticals Q2 net loss narrows
Reuters · 1d ago
Anebulo Pharmaceuticals Announces Voluntary Delisting From Nasdaq
Benzinga · 1d ago
ANEBULO PHARMACEUTICALS INC - BOARD APPROVES VOLUNTARY DELISTING FROM NASDAQ - SEC FILING
Reuters · 1d ago
ANEBULO PHARMACEUTICALS REPORTS SECOND QUARTER FISCAL YEAR 2026 FINANCIAL RESULTS AND RECENT UPDATES
Reuters · 1d ago
ANEBULO PHARMACEUTICALS, INC. Q2 EPS USD -0.05
Reuters · 1d ago
Press Release: Anebulo Pharmaceuticals Reports Second Quarter Fiscal Year 2026 Financial Results and Recent Updates
Dow Jones · 1d ago
Press Release: Anebulo Pharmaceuticals Reports -2-
Dow Jones · 1d ago
Weekly Report: what happened at ANEB last week (0202-0206)?
Weekly Report · 5d ago
12 Health Care Stocks Moving In Friday's Intraday Session
Benzinga · 02/06 17:05
Anebulo Pharmaceuticals Announces Voluntary Nasdaq Delisting Plan
TipRanks · 02/06 14:46
Anebulo Pharmaceuticals to voluntarily delist from Nasdaq
TipRanks · 02/06 14:05
Anebulo Pharmaceuticals Voluntarily Delisting Common Shares From Nasdaq, Effective Feb. 27
Benzinga · 02/06 14:02
BRIEF-Anebulo Pharmaceuticals Announces Intention To Voluntarily Delist From Nasdaq And Deregister With SEC
Reuters · 02/06 14:01
More
Webull provides a variety of real-time ANEB stock news. You can receive the latest news about Anebulo Pharmaceuticals Inc through multiple platforms. This information may help you make smarter investment decisions.
About ANEB
Anebulo Pharmaceuticals, Inc. is a clinical-stage biotechnology company. It is engaged in developing treatments for cannabis toxicity, such as unintentional cannabis poisoning, acute cannabinoid intoxication (ACI) and the landscape of acute cannabis-induced conditions. Its lead product candidate is selonabant, a potent, small molecule antagonist of cannabinoid binding receptor type-1 (CB1), the primary receptor involved in the psychotropic effects of cannabinoids, with the potential to address the unmet medical need for a therapy to treat cannabis toxicity. Selonabant is orally bioavailable, rapidly absorbed, and has also been formulated for intravenous administration. Selonabant is intended to rapidly reverse the negative effects of cannabis-induced toxicity and reduce time to recovery. It is also prioritizing the advancement of a selonabant intravenous (IV) formulation as a potential treatment for pediatric patients with cannabis-induced CNS depression.